Psoriasis meds may quietly shield arteries, small study hints

NCT ID NCT07169682

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study checked if newer psoriasis drugs (IL17/23 inhibitors) also improve artery stiffness, a sign of heart disease. Researchers followed 66 people with moderate-to-severe psoriasis for a year, measuring pulse wave velocity (PWV) and other markers. The goal was to see if these drugs might have hidden heart benefits beyond clearing skin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IL17 or IL23 inhibitor (drug)

What this could lead to

If the drugs improve artery stiffness, it could suggest they also lower heart disease risk in people with psoriasis.

What could go wrong

This is a small, observational study, not a large trial. It only measured a marker (artery stiffness), not actual heart attacks or strokes, so the real benefit is uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Andreas Sygros Hospital

    Athens, 17124, Greece